The PAUSE-URO study evaluated the safety of a new protocol for patients using direct oral anticoagulants (DOACs) prior to elective urologic surgery.

Patients with connective tissue disease-associated PAH have 1-, 3-, and 5-year survival rates similar to those with idiopathic PAH.

(HealthDay News) — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for weight loss appear to be similarly effective among adults across ages, races, and starting weights, according to a review ...

Nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential treatment for adults with systemic lupus erythematosus (SLE). Fast Track designation is designed to ...

Pulmonary involvement is highly prevalent in individuals with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), affecting 82.7% of patients with granulomatosis with polyangiitis ...

Prevalence of hypertension, diabetes, and obesity estimated to increase, while hypercholesterolemia set to decline. (HealthDay News) — For women and girls, the prevalence of cardiovascular risk ...

Patients with cancer undergoing individually tailored exercise intervention also reported less mental fatigue.

TRT use prior to total knee arthroplasty linked to increased risk for medical, periprosthetic complications. (HealthDay News) — Testosterone replacement therapy (TRT) before total knee arthroplasty ...

A web-based system based on optimized models from 3 clinical scenarios may support clinical decision-making for personalized MPA therapy. A machine learning-driven framework accurately predicts ...

The FDA accepted a Biologics License Application for imlifidase for the desensitization treatment of highly sensitized adult kidney transplant patients.

To date, no phase 3 trial has demonstrated a significant survival benefit with any combinatorial therapy for patients with renal cell carcinoma (RCC) in the adjuvant setting. For patients with ...

The FDA grants Fast Track designation to nipocalimab for systemic lupus erythematosus following positive results from the phase 2b JASMINE trial.